# "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

> **NCT05299580** · PHASE2 · WITHDRAWN · sponsor: **Fondazione Melanoma Onlus**

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT05299580
- **Lead sponsor:** Fondazione Melanoma Onlus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02-18
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of enrollment
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05299580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05299580, ""Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05299580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*